Revenue slipped, but net income surged as compensation costs fell sharply.
NUTX Nutex Health Inc.
XNAS
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
NUTX
—
—
What changed
Recent filings, trades and moves- Nov 5 8-K: Earnings results
- Nov 5 Quarterly report (10-Q) filed
Key stats
Related
About
- Industry (SIC)
- SERVICES-BUSINESS SERVICES, NEC (7389) · industry map
- Exchange
- XNAS
- Market Cap
- $1.2B
- Employees
- 944
- List Date
- 2022-04-04
- CIK
- 0001479681
- Last Earnings
- Aug 6
- Headquarters
- Houston, TX
- Homepage
- https://www.nutexhealth.com
Nutex Health Inc is a physician-led, healthcare services and operations company with various hospital facilities in the U.S. states (hospital division), and a primary care-centric, risk-bearing population health management division. The company has three segments: the hospital division, the PHM division, and the real estate division. The hospital division implements and operates health care models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management (PHM) division owns and operates provider networks such as independent ph…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|
| Jan | -- | -32.66% | -35.00% | 37.18% | 0.40% | -7.52% |
| Feb | -- | 3.79% | -4.48% | 12.02% | -31.50% | -5.04% |
| Mar | -- | -22.90% | -15.13% | -9.02% | -19.18% | -16.56% |
| Apr | -76.45% | -42.17% | -57.54% | 54.02% | 21.09% | -20.21% |
| May | 0.00% | -18.56% | 12.62% | 42.16% | -7.49% | 5.75% |
| Jun | -70.06% | -1.40% | -12.51% | -25.88% | 33.49% | -15.27% |
| Jul | -14.01% | -3.39% | 34.78% | -35.65% | -22.27% | -8.11% |
| Aug | -6.92% | -30.74% | 175.29% | -0.25% | 23.43% | 32.16% |
| Sep | -42.08% | -26.90% | 2.50% | 27.68% | 12.98% | -5.16% |
| Oct | -44.86% | -0.14% | 8.41% | 17.87% | -5.73% | -4.89% |
| Nov | 91.26% | -19.06% | 64.60% | -12.60% | 4.61%* | 25.76% |
| Dec | 4.97% | -12.71% | -15.67% | 37.67% | -- | 3.57% |
| Total | -96.38% | -91.36% | 26.16% | 163.73% | -11.15% | -1.80% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $198.53
SMA 50: $203.20
SMA 200: $151.46
Current: $194.16
EMA 12: $195.76
EMA 26: $199.18
MACD: -3.4237 | Signal: -1.6056
BEARISH
ADX (14): 18.36
RANGE
+DI: 19.59
−DI: 25.70
Momentum Oscillators
RSI (14): 47.62
NEUTRAL
Stoch %K: 31.66
Stoch %D: 32.58
Williams %R: -56.07
Volume & Volatility
BB Upper: $218.06
BB Lower: $179.00
NEUTRAL
OBV: 1,866,258
Vol SMA 20: 138,107
Vol ROC: -21.98%
ATR: $14.37
True Range: $16.07
HV 20: 83.8%
HV 30: 71.0%
HV 60: 59.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-11T00:00:00 – 2026-11-09T00:00:00
AI Analysis
Written before NUTX’s Nov 5 earnings report, so it doesn’t reflect the results.
Here is the comprehensive stock analysis report for NUTX:
Executive Summary
Confidence Level: 6/10
Overall assessment: BEARISH due to recent negative news headlines, high volatility, and bearish momentum signals.
Key drivers and primary risks:
- Recent negative news headlines suggesting securities fraud investigations
- High volatility indicating increased market uncertainty
- Bearish momentum signals from MACD and RSI
2-3 sentence investment thesis: NUTX's current price action is driven by negative news sentiment, which may lead to further declines unless the company can address these concerns. The stock's high volatility and bearish momentum suggest a cautious approach is warranted.
Recent news sentiment impact: Bearish news headlines have contributed significantly to NUTX's recent decline.
Technical Analysis
Trend Direction: Short-term: Downtrend, Medium-term: Downtrend, Long-term: Uptrend
Support/Resistance Levels:
- Key price levels: $94.26 (SMA 20), $110.15 (SMA 50), and $117.56 (SMA 200)
- Resistance: $102.11 (upper Bollinger Band)
Momentum Signals: RSI interpretation: Neutral (50.67) with no clear buy or sell signal. MACD signal: Bearish crossover (-3.45 / Signal: 1.86). Bollinger Bands position: Squeeze, indicating potential price action.
Volume Analysis: Volume is trending upward, but the OBV indicates a decline in buying pressure.
News & Sentiment Analysis
Recent Headlines Summary: Negative news headlines about securities fraud investigations have dominated the news.
Sentiment Assessment: Overall sentiment is NEGATIVE due to the recent negative news headlines and bearish momentum signals.
Catalyst Identification: No upcoming events or earnings dates available.
Market Narrative: The recent negative news has outweighed any positive fundamental factors, leading to a decline in NUTX's price action.
Risk & Volatility Assessment
Beta Interpretation: High risk due to beta value (1.36) indicating increased volatility relative to the market.
Volatility Regime: Current volatility is higher than historical levels.
Options Market Signals:
- IV rank: 74.2%
- Put/call ratio: 0.83
- Unusual activity: No significant unusual options activity detected
Downside Protection: Support levels at $94.26 (SMA 20) and $86.41 (lower Bollinger Band).
Market Context & Positioning
Sector Performance: NUTX is underperforming its sector.
Institutional Activity: No significant institutional buying or selling detected.
Correlation Analysis: Correlation with SPY is relatively low at 0.25, indicating some independence from market trends.
Relative Valuation: The stock is trading within a range and may require additional catalysts to break out.
Key Levels & Action Items
Critical Price Levels:
- Support: $94.26 (SMA 20) and $86.41 (lower Bollinger Band)
- Resistance: $102.11 (upper Bollinger Band)
Breakout/Breakdown Levels: No significant breakout or breakdown levels detected.
Time-Sensitive Catalysts: None available.
Risk Management: Stop-loss levels should be set near the support levels ($94.26 and $86.41), with position sizing considerations for larger losses.
Generated
News
All NUTX news →
NUTX Options Activity & IV Rank
Loading options activity...
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.7698
Alpha: 71.42%
Correlation: 0.2682
R-Squared: 7.2%
Stock Volatility: 90.8%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own NUTX
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $8.9M | #1659 of 3716 | -41.8% | 13F | |
| Citadel Hedge fund Ken Griffin | $3.1M | #2491 of 6285 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $12K | #3926 of 4729 | 0.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
NUTX Institutional Ownership (13F)
Filings for 2026-06-30 · 65 already for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
NUTX Insider Trading (Form 4)
Latest: 2026-09-18Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | Scott J Saunders | Director | Sell (S) | −203 | $214.25 | -$43.5K | EDGAR |
| 2026-08-03 | Cheryl Yvonne Grenas | Director | Exer (M) | +603 | — | EDGAR | |
| 2026-08-03 | Scott J Saunders | Director | Exer (M) | +603 | — | EDGAR | |
| 2026-08-03 | Frank E Jaumot | Director | Exer (M) | +603 | — | EDGAR | |
| 2026-08-03 | Michael Lee Reed | Director | Exer (M) | +603 | — | EDGAR | |
| 2026-06-04 | Kelvin Spears | Director | Other (J) | +2,519 | — | EDGAR | |
| 2026-05-29 | Thomas T. Vo | Chief Executive Officer | Other (J) | +75,747 | — | EDGAR | |
| 2026-04-24 | Cheryl Yvonne Grenas | Director | Grant (A) | +823 RSU | — | EDGAR | |
| 2026-04-24 | Michael Lee Reed | Director | Grant (A) | +823 RSU | — | EDGAR | |
| 2026-04-24 | Frank E Jaumot | Director | Grant (A) | +823 RSU | — | EDGAR | |
| 2026-04-24 | Scott J Saunders | Director | Grant (A) | +823 RSU | — | EDGAR | |
| 2026-04-10 | Thomas T. Vo | Chief Executive Officer | Other (J) | +184,071 | — | EDGAR | |
| 2026-03-24 | Wesley Shane Bamburg | Chief Operating Officer | Exer (M) | +2,411 RSU | — | EDGAR | |
| 2026-03-23 | Frank E Jaumot | Director | Buy (P) | +150 | $93.56 | $14.0K | EDGAR |
| 2026-03-23 | Warren Hosseinion | President | Buy (P) | +252 | $94.07 | $23.7K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
NUTX Insider Holdings
12 insiders · @ $194.16
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Thomas T. Vo | Chief Executive Officer | 2,281,060 | $442.89M | $983.8K | 15 | 2026-05-29 |
| 2 | Michael L. Chang | Chief Medical Officer | 82,356 | $15.99M | $0 | 4 | 2026-03-11 |
| 3 | Kelvin Spears | Director | 34,656 | $6.73M | $945 | 4 | 2026-06-04 |
| 4 | Jon Christian Bates | Chief Financial Officer | 8,305 | $1.61M | $221.7K | 8 | 2026-03-11 |
| 5 | Warren Hosseinion | President | 7,765 | $1.51M | $2.14M | 11 | 2026-03-23 |
| 6 | Joshua DeTillio | Chief Operating Officer | 6,933 | $1.35M | $78.2K | 5 | 2025-04-14 |
| 7 | Elisa V Luqman | Chief Legal Officer - SEC | 3,706 | $719.6K | $0 | 4 | 2026-03-11 |
| 8 | Pamela W. Montgomery | Chief Legal Officer-Healthcare | 2,758 | $535.5K | $12.2K | 7 | 2026-03-16 |
| 9 | Frank E Jaumot | Director | 753 | $146.2K | $14.0K | 4 | 2026-08-03 |
| 10 | Cheryl Yvonne Grenas | Director | 737 | $143.1K | $4.3K | 6 | 2026-08-03 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
NUTX Board & Officers
As of SEC filings through Sep 18, 2026Directors 7
- Warren Hosseinion · listed since Apr 2020
- Cheryl Yvonne Grenas · since Apr 1, 2022
- Michael Lee Reed · since Apr 1, 2022
- Thomas T. Vo · since Apr 1, 2022
- Kelvin Spears · since Feb 28, 2024
- Scott J Saunders · since Apr 11, 2024
- Frank E Jaumot · since Jul 14, 2025
Officers 7
- Thomas T. Vo · Chief Executive Officer · listed since May 2022
- Warren Hosseinion · President · listed since Apr 2022
- Jon Christian Bates · Chief Financial Officer · since Jul 8, 2022
- Wesley Shane Bamburg · Chief Operating Officer · since Oct 15, 2025
- Michael L. Chang · Chief Medical Officer · since Apr 1, 2022
- Elisa V Luqman · Chief Legal Officer - SEC · listed since Apr 2022
- Pamela W. Montgomery · Chief Legal Officer-Healthcare · listed since Jun 2024
Changes in the last 10 years (55)
| Oct 15, 2025 | Wesley Shane Bamburg became Chief Operating Officer |
| Jul 14, 2025 | Frank E Jaumot became a director |
| Jul 8, 2025 | The company announced the departure of Joshua DeTillio as Chief Operating Officer in an SEC filing |
| Jun 28, 2024 | Pamela W. Montgomery listed as Chief Legal Officer-Healthcare (previously Chief Legal Officer) in SEC filings |
| Apr 11, 2024 | Scott J Saunders became a director |
| Feb 28, 2024 | The company announced the departure of Danniel Stites from the board in an SEC filing |
| Feb 28, 2024 | Kelvin Spears became a director |
| Nov 21, 2023 | Thomas T. Vo no longer listed as a 10% owner in SEC filings |
| Oct 2, 2023 | Joshua DeTillio became Chief Operating Officer |
| May 10, 2023 | Pamela W. Montgomery listed as Chief Legal Officer (previously Chief Legal Off. & Secretary) in SEC filings |
| Apr 1, 2023 | Danniel Stites became a director |
| Mar 31, 2023 | The company announced the departure of Matthew Stephen Young from the board in an SEC filing |
| Aug 5, 2022 | Thomas T. Vo first listed as a 10% owner in an SEC filing |
| Jul 8, 2022 | Jon Christian Bates became Chief Financial Officer |
| May 11, 2022 | Thomas T. Vo listed as Chief Executive Officer (previously Chairman, CEO) in SEC filings |
| Apr 8, 2022 | Warren Hosseinion listed as President (previously Chief Executive Officer) in SEC filings |
| Apr 8, 2022 | Lawrence Schimmel listed as Chief Medical Information Off (previously Chief Executive Officer) in SEC filings |
| Apr 8, 2022 | Frederick Sternberg first on file as President of subsidiary |
| Apr 8, 2022 | Elisa V Luqman no longer listed as a director in SEC filings |
| Apr 8, 2022 | Elisa V Luqman listed as Chief Legal Officer - SEC (previously Chief Financial Officer) in SEC filings |
| Apr 1, 2022 | Thomas T. Vo became a director |
| Apr 1, 2022 | Thomas T. Vo became Chairman, CEO |
| Apr 1, 2022 | The company announced the departure of Michael Bowen as Chief Financial Officer in an SEC filing |
| Apr 1, 2022 | Premier Macy Management Holdings, LLC became a 10% owner |
| Apr 1, 2022 | Pamela W. Montgomery became Chief Legal Off. & Secretary |
| Apr 1, 2022 | Micro Hospital Holding LLC became a 10% owner |
| Apr 1, 2022 | Michael Lee Reed became a director |
| Apr 1, 2022 | Michael L. Chang became Chief Medical Officer |
| Apr 1, 2022 | Matthew Stephen Young became a director |
| Apr 1, 2022 | Claudia Denise Pufal became Chief Operating Officer |
| Apr 1, 2022 | Cheryl Yvonne Grenas became a director |
| Dec 21, 2021 | Warren Hosseinion no longer listed as a 10% owner in SEC filings |
| Dec 21, 2021 | Warren Hosseinion first listed as Chief Executive Officer in an SEC filing |
| Oct 1, 2021 | Anh Nguyen became President of subsidiary |
| Feb 26, 2021 | Dominis-Embree AHA Investor, LLC became a 10% owner |
| Feb 25, 2021 | Robert Chan became a director |
| Feb 25, 2021 | Michael Bowen became Chief Financial Officer |
| Feb 25, 2021 | Andrew Barnett became EVP of Corp Development |
| Feb 3, 2021 | Warren Hosseinion first listed as a 10% owner in an SEC filing |
| Sep 9, 2020 | Lawrence Schimmel listed as Chief Executive Officer (previously Chief Medical Officer) in SEC filings |
| Jun 18, 2020 | Lawrence Schimmel no longer listed as a director in SEC filings |
| Apr 28, 2020 | Warren Hosseinion first listed as a director in an SEC filing |
| Nov 8, 2019 | Elisa V Luqman no longer listed as a 10% owner in SEC filings |
| Nov 8, 2019 | Elisa V Luqman listed as Chief Financial Officer (previously EVP and General Counsel) in SEC filings |
| Oct 29, 2019 | Terence Martin Breslin became a director |
| Oct 29, 2019 | Terence Martin Breslin became a 10% owner |
| Oct 29, 2019 | Mitchell Creem became a director |
| Oct 29, 2019 | Mark Fawcett became a director |
| Oct 29, 2019 | Lawrence Schimmel became a director |
| Oct 29, 2019 | Lawrence Schimmel became Chief Medical Officer |
| Oct 29, 2019 | Jacob Margolin became a director |
| Oct 29, 2019 | Jacob Margolin became Chief Executive Officer |
| Oct 29, 2019 | David Meiri became a director |
| Feb 14, 2017 | Kathleen Shepherd became VP Operations HealthDatix Inc |
| Feb 14, 2017 | Jerry Robinson became Pres & CEO HelathDatix Inc. |
Not reported recently (17)
- Mitchell Creem · Last reported as a director in an SEC filing dated Jun 17, 2024
- John J Waters · Last reported as a director in an SEC filing dated Jun 29, 2023
- Premier Macy Management Holdings, LLC · Last reported as a 10% owner in an SEC filing dated Dec 14, 2022
- Micro Hospital Holding LLC · Last reported as a 10% owner in an SEC filing dated Aug 5, 2022
- Lawrence Schimmel · Last reported as Chief Medical Information Off in an SEC filing dated Aug 2, 2022
- Andrew Barnett · Last reported as EVP of Corp Development in an SEC filing dated Apr 8, 2022
- Frederick Sternberg · Last reported as President of subsidiary in an SEC filing dated Apr 8, 2022
- Claudia Denise Pufal · Last reported as Chief Operating Officer in an SEC filing dated Apr 5, 2022
- Anh Nguyen · Last reported as President of subsidiary in an SEC filing dated Mar 14, 2022
- Mark Fawcett · Last reported as a director in an SEC filing dated Dec 21, 2021
- Robert Chan · Last reported as a director in an SEC filing dated Dec 21, 2021
- Dominis-Embree AHA Investor, LLC · Last reported as a 10% owner in an SEC filing dated May 25, 2021
- David Meiri · Last reported as a director in an SEC filing dated Feb 4, 2021
- Terence Martin Breslin · Last reported as a director in an SEC filing dated Feb 4, 2021
- Jacob Margolin · Last reported as a director in an SEC filing dated Sep 29, 2020
- Jerry Robinson · Last reported as Pres & CEO HelathDatix Inc. in an SEC filing dated Sep 13, 2017
- Kathleen Shepherd · Last reported as VP Operations HealthDatix Inc in an SEC filing dated Sep 13, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
69 ETFs hold NUTX
25 shown · $188.88M total exposure · 0.05% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | AVUV Avantis U.S. Small Cap Value ETF | Avantis | 0.18% | $56.7M | $31.6B | 2026-11-05 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $29.9M | — | 2026-09-30 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.03% | $23.4M | $76.6B | 2026-11-06 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $10.9M | — | 2026-09-30 |
| 5 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.06% | $8.5M | $13.7B | 2026-11-06 |
| 6 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.56% | $7.4M | $1.3B | 2026-11-06 |
| 7 | CALF Pacer US Small Cap Cash Cows 100 ETF | Nport | 0.18% | $6.5M | — | 2026-07-31 |
| 8 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.03% | $6.2M | — | 2026-09-30 |
| 9 | BSVO EA Bridgeway Omni Small-Cap Value ETF | Nport | 0.23% | $5.5M | — | 2026-06-30 |
| 10 | SFLO VictoryShares Small Cap Free Cash Flow ETF | Nport | 0.81% | $4.9M | — | 2026-06-30 |
| 11 | XHS State Street® SPDR® S&P® Health Care Services ETF | SPDR (State Street) | 1.58% | $3.8M | $242.8M | 2026-11-05 |
| 12 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.26% | $3.6M | $1.4B | 2026-11-06 |
| 13 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.23% | $2.8M | $1.2B | 2026-11-06 |
| 14 | RNIN Bushido Capital US SMID Cap Equity ETF | Nport | 1.09% | $2.0M | — | 2026-07-31 |
| 15 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $2.0M | — | 2026-11-05 |
| 16 | AVSC Avantis U.S. Small Cap Equity ETF | Avantis | 0.06% | $1.9M | $3.2B | 2026-11-05 |
| 17 | PSC Principal U.S. Small-Cap ETF | Nport | 0.08% | $1.9M | — | 2026-06-30 |
| 18 | JPSE JPMorgan Diversified Return U.S. Small Cap Equity ETF | JPMorgan | 0.30% | $1.7M | $560.5M | 2026-11-06 |
| 19 | VFMF Vanguard U.S. Multifactor ETF | Vanguard | 0.15% | $1.7M | — | 2026-11-05 |
| 20 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.08% | $1.4M | — | 2026-11-05 |
| 21 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.14% | $1.4M | $1.0B | 2026-11-05 |
| 22 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $1.3M | $93.2B | 2026-11-06 |
| 23 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $1.2M | — | 2026-11-05 |
| 24 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.07% | $1.2M | — | 2026-09-30 |
| 25 | EES WisdomTree U.S. SmallCap Fund | Nport | 0.16% | $1.1M | — | 2026-06-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
NUTX vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| OSCR Oscar Health, Inc. | $9.5B | — | +32.3% | +114.7% | 4 |
| ENVA Enova International, Inc. | $4.2B | 11.6 | +23.2% | +3.9% | 24 |
| AGX Argan, Inc | $3.9B | 24.2 | +29.0% | −6.0% | 74 |
| APAM ARTISAN PARTNERS ASSET MANAGEMENT INC. | $2.8B | 9.4 | +8.7% | −3.8% | 44 |
| PGNY Progyny, Inc. Common Stock | $2.6B | 33.0 | +5.5% | +39.7% | 9 |
| MD Pediatrix Medical Group, Inc. | $2.4B | 17.1 | +1.9% | +47.9% | 46 |
| HRMY Harmony Biosciences Holdings, Inc. Commo | $1.9B | 11.2 | +19.8% | −9.6% | 40 |
| NUTX Nutex Health Inc. Common Stock | $1.2B | — | — | +31.0% | — |
| COLL Collegium Pharmaceutical, Inc. Common St | $752M | 20.1 | +14.3% | −45.7% | 38 |
| Peer median | $2.7B | 17.1 | +17.1% | +0.1% | 39 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.